Stay updated on Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.

Latest updates to the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedVersion 8 (2024-10-09) adds new sections such as Document Section, Participant Flow, Baseline Characteristics, Outcome Measures (Results), Adverse Events, and Limitations and Caveats, and updates multiple areas including Study Identification, Study Status, Study Description, Arms and Interventions, and Contacts/Locations.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check37 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference11%

- Check44 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

- Check58 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.7%

- Check65 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%

- Check72 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information.SummaryDifference19%

Stay in the know with updates to Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.